EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Targeted Protein Degradation (TPD) for Immunotherapy: Understanding Proteolysis Targeting Chimera-Driven Ubiquitin-Proteasome Interactions

Rajamanikkam Kamaraj iD, Subhrojyoti Ghosh iD, Souvadra Das, Shinjini Sen, Priyanka Kumar, Madhurima Majumdar, Renesa Dasgupta, Sampurna Mukherjee, Shrimanti Das, Indrilla Ghose, Petr Pavek, Muruga Poopathi Raja Karuppiah und 2 weitere

Bioconjugate Chemistry · 2024

DOI: 10.1021/acs.bioconjchem.4c00253 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Bioconjugate Chemistry, 2024. Verfasst von Rajamanikkam Kamaraj und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Toxicology, Faculty of Pharmacy, Charles University in Prague, Heyrovskeho 1203, 50005 Hradec Kralove, Czech Republic. Hauptthemen laut MEDLINE: Proteolysis, Proteasome Endopeptidase Complex, Immunotherapy, Ubiquitin. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 212 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Commission, Grantová Agentura, Univerzita Karlova, National Research Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Targeted protein degradation or TPD, is rapidly emerging as a treatment that utilizes small molecules to degrade proteins that cause diseases. TPD allows for the selective removal of disease-causing proteins, including proteasome-mediated degradation, lysosome-mediated degradation, and autophagy-mediated degradation. This approach has shown great promise in preclinical studies and is now being translated to treat numerous diseases, including neurodegenerative diseases, infectious diseases, and cancer. This review discusses the latest advances in TPD and its potential as a new chemical modality for immunotherapy, with a special focus on the innovative applications and cutting-edge research of PROTACs (Proteolysis TArgeting Chimeras) and their efficient translation from scientific discovery to technological achievements. Our review also addresses the significant obstacles and potential prospects in this domain, while also offering insights into the future of TPD for immunotherapeutic applications.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ProteolysisProteasome Endopeptidase ComplexImmunotherapyUbiquitinHumansAnimalsNeoplasmsProteolysis Targeting Chimera

Substanzen

Proteasome Endopeptidase ComplexUbiquitinProteolysis Targeting Chimera

Autor:innen und Institutionen

  • Department of Pharmacology and Toxicology, Faculty of Pharmacy, Charles University in Prague, Heyrovskeho 1203, 50005 Hradec Kralove, Czech Republic.
  • Department of Biotechnology, Indian Institute of Technology Madras, Chennai 600036, India.
  • Department of Biotechnology, Heritage Institute of Technology, Kolkata 700107, India.
  • Department of Chemistry, School of Physical Sciences, Central University of Kerala, Tejaswini Hills, Periye, Kasaragod District, Kerala 671320, India.
  • Discipline of Medical Biochemistry, School of Laboratory Medicine and Medical Sciences, College of Health Sciences, Howard College Campus, University of KwaZulu-Natal, Durban 4041, South Africa.
  • Department of Chemical Pathology, School of Pathology, Faculty of Health Sciences, University of the Free State, Bloemfontein, Free State 9300, South Africa.

ORCID-Profile: Rajamanikkam Kamaraj, Subhrojyoti Ghosh, Anil A Chuturgoon, Krishnan Anand

Förderung

  • European Commission
  • Grantová Agentura, Univerzita Karlova
  • National Research Foundation
  • Universiteit van die Vrystaat

Zitieren

APA

Kamaraj, R., Ghosh, S., Das, S., Sen, S., Kumar, P., Majumdar, M., Dasgupta, R., Mukherjee, S., Das, S., Ghose, I., Pavek, P., Raja Karuppiah, M. P., Chuturgoon, A. A., & Anand, K. (2024). Targeted Protein Degradation (TPD) for Immunotherapy: Understanding Proteolysis Targeting Chimera-Driven Ubiquitin-Proteasome Interactions. Bioconjugate Chemistry. https://doi.org/10.1021/acs.bioconjchem.4c00253

Vancouver

Kamaraj R, Ghosh S, Das S, Sen S, Kumar P, Majumdar M, et al. Targeted Protein Degradation (TPD) for Immunotherapy: Understanding Proteolysis Targeting Chimera-Driven Ubiquitin-Proteasome Interactions. Bioconjugate Chemistry. 2024. doi:10.1021/acs.bioconjchem.4c00253

BibTeX
@article{Kamaraj2024,
  author = {Kamaraj, Rajamanikkam and Ghosh, Subhrojyoti and Das, Souvadra and Sen, Shinjini and Kumar, Priyanka and Majumdar, Madhurima and Dasgupta, Renesa and Mukherjee, Sampurna and Das, Shrimanti and Ghose, Indrilla and Pavek, Petr and Raja Karuppiah, Muruga Poopathi and Chuturgoon, Anil A and Anand, Krishnan},
  title = {Targeted Protein Degradation (TPD) for Immunotherapy: Understanding Proteolysis Targeting Chimera-Driven Ubiquitin-Proteasome Interactions},
  journal = {Bioconjugate Chemistry},
  year = {2024},
  doi = {10.1021/acs.bioconjchem.4c00253}
}
Kostenlos starten →